濮阳东方看妇科评价很不错濮阳东方医院男科看阳痿价格偏低,濮阳东方男科技术权威,濮阳东方医院男科看早泄非常可靠,濮阳东方医院割包皮技术,濮阳东方男科口碑好不好,濮阳东方医院妇科做人流收费便宜,濮阳东方医院男科收费很低

The UK has accused Syria and Russia of preventing independent chemical weapons experts from entering the city of Douma, hit by a suspected gas attack that Western leaders have blamed on the Syrian government.A fact-finding team from the Organization for the Prohibition of Chemical Weapons (OPCW) arrived in Syria on Saturday, the same day the US, UK and France carried out airstrikes against Syrian government targets in response to the April 7 attack in Douma.But by Monday, the team had still not been granted safe passage, according to the UK envoy to the OPCW, Peter Wilson. The US expressed concerns that Russia may have tampered with evidence at the site.The OPCW team is tasked with determining whether banned substances were used in the attack, a charge that both Syria and its most powerful ally, Russia, have vehemently denied.Syria's Deputy Foreign Minister Fayssal Mikdad said Monday his country was ready to facilitate the OPCW team in any way to carry out its mission, the state-run SANA news agency reported, while Kremlin spokesman Dmitry Peskov did not respond directly to CNN's question on whether Russia had blocked the experts. Peskov said only that Russia was against "groundless" accusations about who was responsible for the attack.Russian Deputy Foreign Minister Sergei Ryabkov said the OPCW team's arrival was hampered by the weekend air strikes, state media RIA Novosti reported.The suspected chemical attack is the latest issue to heighten tensions between Russia and Western powers. More than 100 Russian diplomats were expelled from more than 20 countries in March over the poisoning of a Russian ex-spy on British soil, which the UK and US has blamed on the Russian government. Russia denies the accusations.Russian officials last week claimed British intelligence agencies had helped stage the suspected chemical attack in Douma."Yet again, Russia is spreading conspiracy theories and misinformation designed to undermine the integrity of the OPCW's fact finding mission," Wilson said in a statement."A significant body of information, including intelligence, indicates the Syrian regime is responsible for this latest attack."The US envoy to the OPCW, Kenneth D. Ward, said he was concerned that Russia may have interfered with the site of the Douma attack."We are concerned they may have tampered with it with the intent of thwarting the efforts of the OPCW Fact Finding Mission to conduct an effective investigation. This raises serious questions about the ability of the (team) to do its job," he said in a statement Monday.Russian Foreign Minister Sergey Lavrov said last week his country had sent experts to the site and found "no trace" of chemical weapons use. On Monday, he told the BBC's Hardtalk show that he guaranteed there had been no Russian tampering.Around 75 people, including children, were killed in the Douma assault, UK officials have said, while 500 people were treated in the attack's aftermath with symptoms consistent with chemical weapons exposure, the World Health Organization reported, citing its partners on the ground.The OPCW has recorded more than 390 allegations of chemical weapons use in Syria since its investigation began in 2014, Wilson said. 3222

The Rev. Pat Conroy, the chaplain at the US House of Representatives, has rescinded his resignation in a letter, obtained by CNN, following a week's worth of lawmakers from both parties questioning House Speaker Paul Ryan's request that Conroy step down."At this time, and upon advice of counsel, I herby retract and rescind said resignation for the reasons that follow," Conroy writes in the letter dated Thursday and addressed to Ryan.Conroy, a Jesuit priest, resigned April 15 after he spent nearly seven years praying at the outset of House sessions. He wrote two versions of his resignation letter, which were also obtained by CNN from a congressional source. In the first version, he wrote that Ryan, who is Catholic, should consult with his chief of staff on a resignation date, but the second version stated his last day would be May 24. 853

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274

The resilience of the students and staff at Marjory Stoneman Douglas High School is obvious. They've resumed classes, and their lives, on a campus where 17 of fellow students and teachers were killed in a mass shooting just over a month ago.And now, they'll turn what's normally a private chronicle of high school life -- a yearbook -- into a public testament to pain and perseverance.For the first time, the high school's yearbook is being made available nationally for purchase. In it, the yearbook staff weave a powerful tale of Marjory Stoneman Douglas' strength and resolve, for the whole world to see."We're still here. We still have games going on. We're still making the yearbook. There's still going to be prom," yearbook adviser Sarah Lerner said in a blog post for Walsworth Yearbooks. "We're a very strong community and we're not letting this stop us."Lerner said at first she was hesitant to share the upcoming yearbook, The Aerie, with the public, because there are student pictures and personal stories in it. But she ultimately decided that opening up the yearbook to people outside the school would let them see how much pride the students have in their school."I hope they see how hard the kids have worked and how much love has gone into this book," Lerner said. "I hope that they see all of the wonderful things that we do here, before the (shooting) and since."'It's our story'The Aerie will include coverage of the shooting, pictures from vigils and memorials, a story on students dyeing their hair in honor of the victims, pieces on the surviving students' political activism and highlights from the week they returned to the school.In a special section, each of the mass shooting's 17 victims will be profiled."We have a story to tell and it's our story. No one else will tell it better than we will, because we lived it," Lerner said.People interested in buying a copy of the yearbook can go to yearbookforever.com to place an order. 1966

The University of Washington’s Institute for Health Metrics and Evaluation now projects that 33,000 American lives would be saved between now and October 1 by near universal wearing of masks.The IHME released the updated model on Wednesday.The IHME’s coronavirus projections have been frequently cited in the past by the White House’s coronavirus task force. The group uses state data along with other metrics to create projections on the number of coronavirus-related deaths throughout the US.The projection state that the US is currently on track to have an additional 58,000 coronavirus-related deaths between now and October 1. But that number drops to just 23,000 if masks are universally worn in public. Those figures are on top of the over 121,000 reported coronavirus-related deaths since the beginning of the pandemic.The IHME’s model projects that the US death toll will stay consistent on a per-day basis between now and September, before starting to increase in the fall. But the model projects that fewer than 100 Americans will die per day from coronavirus by September if masks are worn.The IHME’s latest model projects that coronavirus-related deaths will continue to surge in the states of Texas, Arizona and Florida in the coming weeks, while leveling or dropping off in many other states.To see a state-by-state breakdown of the IHME’s projections, click here.Last month, a study in the Lancet found that the use of masks and respirators by those infected with the virus reduced the risk of spreading the infection by 85%. The authors analyzed data that showed that N95 respirators in healthcare settings were up to 96% effective. Other masks were found to be 77% effective. 1701